Aurinia Pharmaceuticals (AUPH – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on February 27. Analyst Joseph Schwartz from Leerink Partners maintained a Buy rating on the stock and has a $10.00 price target.
Joseph Schwartz’s rating is based on Aurinia Pharmaceuticals’ solid performance in 2024 and its promising outlook for the future. The company reported Lupkynis sales that aligned with expectations, marking a 36% year-over-year growth, which reflects a strong year despite earlier challenges during its launch. Schwartz highlights Aurinia’s strategic focus on expanding its business at academic and lupus nephritis centers, leveraging new treatment guidelines, and utilizing long-term study data to enhance patient care continuity.
Additionally, the company’s guidance for 2025, though slightly below consensus, indicates a continued growth trajectory with an expected 13% increase in sales. The anticipation of upcoming data from AUR200, a novel therapeutic candidate, further supports the potential for future growth. These factors contribute to Schwartz’s confidence in maintaining a Buy rating, despite a slight reduction in the price target from $12 to $10.
In another report released on February 27, TD Cowen also maintained a Buy rating on the stock with a $11.00 price target.
AUPH’s price has also changed moderately for the past six months – from $6.730 to $7.550, which is a 12.18% increase.